Results of a clinical evaluation of the safety and efficacy of the therapeutic drug candidate Roscovitine in people with cystic fibrosis.
Lung infection by Pseudomonas aeruginosa in children with cystic fibrosis: risk factors and impact on lung function
Using an Antibiotic Treatment Called Amikacin Liposome Inhalation Suspension (or ALIS) for Chronic Infection With Pseudomonas aeruginosa in People With Cystic Fibrosis for 2 years
Focusing on tiny compounds in exhaled breath, can they help detect bacteria in people with cystic fibrosis?
Pseudomonas aeruginosa infection, but not CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis
